Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2021 Jun 28:2021.03.20.436163. Originally published 2021 Mar 21. [Version 2] doi: 10.1101/2021.03.20.436163

The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells

Xiaodong Zhuang, Senko Tsukuda, Florian Wrensch, Peter AC Wing, Mirjam Schilling, James M Harris, Helene Borrmann, Sophie B Morgan, Jennifer L Cane, Laurent Mailly, Nazia Thakur, Carina Conceicao, Harshmeena Sanghani, Laura Heydmann, Charlotte Bach, Anna Ashton, Steven Walsh, Tiong Kit Tan, Lisa Schimanski, Kuan-Ying A Huang, Catherine Schuster, Koichi Watashi, Timothy SC Hinks, Aarti Jagannath, Sridhar R Vausdevan, Dalan Bailey, Thomas F Baumert, Jane A McKeating
PMCID: PMC7987021  PMID: 33758862

SUMMARY

The COVID-19 pandemic, caused by SARS-CoV-2 coronavirus, is a global health issue with unprecedented challenges for public health. SARS-CoV-2 primarily infects cells of the respiratory tract, via Spike glycoprotein binding angiotensin-converting enzyme (ACE2). Circadian rhythms coordinate an organism’s response to its environment and can regulate host susceptibility to virus infection. We demonstrate a circadian regulation of ACE2 in lung epithelial cells and show that silencing BMAL1 or treatment with a synthetic REV-ERB agonist SR9009 reduces ACE2 expression and inhibits SARS-CoV-2 entry. Treating infected cells with SR9009 limits viral replication and secretion of infectious particles, showing that post-entry steps in the viral life cycle are influenced by the circadian system. Transcriptome analysis revealed that Bmal1 silencing induced a wide spectrum of interferon stimulated genes in Calu-3 lung epithelial cells, providing a mechanism for the circadian pathway to dampen SARS-CoV-2 infection. Our study suggests new approaches to understand and improve therapeutic targeting of SARS-CoV-2.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES